Study indicates gene editing could restore OTC enzyme activity
Gene editing company iECURE has shared data from the ongoing OTC-HOPE Phase I/II study of ECUR-506, which suggest partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed.
“Long-term restoration of ornithine transcarbamylase activity has the potential to allow infants afflicted with neonatal onset OTC deficiency to live healthier lives unburdened by hyperammonemic crises and ongoing medical management,” said Gabriel Cohn, Chief Medical Officer of iECURE. “The data generated for the first six months post treatment with ECUR-506 continue to be encouraging for us.”
The data presented build upon previously announced preliminary findings, which detailed the complete clinical response for the infant as per study protocol.
Notably, the first patient received a single infusion of the lowest dose (1.3 x 1013GC/kg) of ECUR-506 at 6.5 months of age. At 12 weeks post-ECUR-506 dosing, ammonia scavenger medication was discontinued based on reduced serum glutamine levels, and protein allowance was increased to the age-appropriate level for infants without OTC deficiency.
Treatment with ECUR-506 was generally well tolerated, however, asymptomatic Grade 3 transaminitis was noted at four weeks post ECUR-506 exposure, which resolved by eight weeks post ECUR-506 exposure following immunosuppressive therapy management.
The mean blood urea nitrogen (BUN) level post ECUR-506 treatment was markedly higher in comparison to the pre-treatment mean, which was close to the lower limit of normal. This may suggest increased functional activity, as BUN is usually low in patients who lack the OTC gene due to impaired urea production.
An “exciting option” for OTC deficiency
“The observation at the end of the six-month follow-up period that plasma ammonia levels remained within normal limits following the removal of ammonia scavenger medicines and restoration of a diet with typical protein levels as well as increased blood urea nitrogen levels suggest some OTC enzyme activity may have been restored following treatment with ECUR-506,” said Julien Baruteau, MRC Clinical Scientist Fellow and Group Leader at University College London Great Ormond Street Institute of Child Health and Consultant in Metabolic Medicine at Great Ormond Street Hospital for Children in London, and principal investigator in the study. “For families who have struggled to manage their babies’ health while waiting for liver transplant, currently the only long-term solution for those afflicted with the most severe forms of OTC deficiency, a solution that could restore OTC activity would be an incredibly exciting option.”
ECUR-506 comprises two vectors, an ARCUS nuclease vector targeting gene editing in the well-characterised PCSK9 gene locus and a donor vector that inserts the desired functional OTC gene. iECURE has licensed the ARCUS nuclease for ECUR-506 from Precision BioSciences.
Diana Spencer, Senior Digital Content Editor, DDW
